Paul T Thevenot
Overview
Explore the profile of Paul T Thevenot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
570
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Das S, Finney A, Anand S, Rohilla S, Liu Y, Pandey N, et al.
Nat Metab
. 2024 Sep;
6(10):1939-1962.
PMID: 39333384
The incidence of metabolic dysfunction-associated steatohepatitis (MASH) is on the rise, and with limited pharmacological therapy available, identification of new metabolic targets is urgently needed. Oxalate is a terminal metabolite...
2.
Pandey N, Anand S, Kaur H, Richard K, Chandaluri L, Butler M, et al.
J Thromb Haemost
. 2024 Sep;
22(12):3572-3580.
PMID: 39306095
Background: Patients with metabolic dysfunction-associated steatohepatitis (MASH) are at an increased risk of developing venous thromboembolic events, including deep vein thrombosis (DVT). To date, the study of DVT in MASH...
3.
Stanneart J, Nunez K, Sandow T, Gimenez J, Fort D, Hibino M, et al.
Cancers (Basel)
. 2024 Jan;
16(1).
PMID: 38201639
Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related deaths in the world. Patients with early-stage HCC are treated with liver-directed therapies to bridge or downstage for liver...
4.
Nunez K, Sandow T, Gimenez J, Hibino M, Fort D, Cohen A, et al.
Eur J Cancer
. 2023 Nov;
196:113442.
PMID: 37988841
Background: Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related deaths in the world. Liver-directed therapies, including Yttrium (Y) radioembolization, play an integral role in the management of...
5.
Nunez K, Sandow T, Lakey M, Fort D, Cohen A, Thevenot P
Front Oncol
. 2022 Jul;
12:809860.
PMID: 35785174
Background: Hepatocellular carcinoma is a heterogeneous tumor that accumulates a mutational burden and dysregulated signaling pathways that differ from early to advanced stages. Liver transplant candidates with early-stage hepatocellular carcinoma...
6.
Nunez K, Sandow T, Fort D, Hibino M, Wright P, Cohen A, et al.
Cancer Immunol Immunother
. 2021 Oct;
71(6):1453-1465.
PMID: 34689234
Background: Hepatocellular carcinoma (HCC) patients undergo liver-directed therapy (LDT) to control tumor burden while awaiting liver transplantation with response impacting waitlist survival. In this study, we investigate the link between...
7.
Nunez K, Frank A, Gonzalez-Rosario J, Galliano G, Bridle K, Crawford D, et al.
PLoS One
. 2019 Apr;
14(4):e0216242.
PMID: 31034519
Transplanting donor livers with severe macrosteatosis is associated with increased risk of primary non-function (PNF). The purpose of this study was to identify steatosis-driven biomarkers as a predisposition to severe...
8.
Sandow T, Arndt S, Albar A, DeVun D, Kirsch D, Gimenez J, et al.
Radiology
. 2017 Dec;
286(3):1072-1083.
PMID: 29206595
Purpose To assess response to transcatheter arterial chemoembolization (TACE) based on immune markers and tumor biology in patients with hepatocellular carcinoma (HCC) who were bridged to liver transplantation, and to...
9.
Nunez K, Gonzalez-Rosario J, Thevenot P, Cohen A
Ochsner J
. 2017 Mar;
17(1):56-65.
PMID: 28331449
Background: Cyclin D1 is an important protein for cell cycle progression; however, functions independent of the cell cycle have been described in the liver. Cyclin D1 is also involved in...
10.
Raber P, Sierra R, Thevenot P, Shuzhong Z, Wyczechowska D, Kumai T, et al.
Oncotarget
. 2016 Mar;
7(14):17565-78.
PMID: 27007050
The success of adoptive T cell-based immunotherapy (ACT) in cancer is limited in part by the accumulation of myeloid-derived suppressor cells (MDSC), which block several T cell functions, including T...